A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...

Trial finds weight loss drug taken monthly helps people lose 20% of body weight - The new drug may rival other weight loss ...